Fresenius Kabi has realised plans to launch its 505(b)(2) hybrid bortezomib 3.5mg/vial injectable in the US, after announcing the availability of the “first and only” alternative to Takeda’s Velcade (bortezomib) intravenous injectable.
Fresenius Kabi has realised plans to launch its 505(b)(2) hybrid bortezomib 3.5mg/vial injectable in the US, after announcing the availability of the “first and only” alternative to Takeda’s Velcade (bortezomib) intravenous injectable.
The launch – which bolsters the German firm’s portfolio of oncology products – follows the US Food and Drug Administration...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
